The chemiluminescent microparticle immunoassay (CMIA), which is designed for use on Abbott’s fully-automated Architect family of analyzers, quantitatively determines cardiac troponin I (cTnI) in human plasma and serum for the diagnosis of myocardial infarction (MI).

In addition, cTnI values are used to assess 30-day and 90-day prognosis relative to all-cause mortality and major adverse cardiac events (MACE), including myocardial infarction, revascularization, and cardiac death, in patients who present with symptoms suggestive of acute coronary syndrome (ACS).

University Heart Center cardiology director professor Stefan Blankenberg said compared to current tests, the advantage of high sensitive troponin tests is that clinicians may now more precisely confirm or exclude a heart attack much sooner and with higher accuracy compared to contemporary tests.

"This is important information for patient care because we can pursue treatment if needed or avoid invasive therapy and discharge a patient earlier," Blankenberg added.